丽珠肠乐及莫沙必利治疗肝衰竭42例

Observation of curative effect of Bifidobiogen-Livzon and Mosapride on fouty-two cases with liver failure.

目的观察丽珠肠乐及莫沙必利治疗慢加急性(亚急性)肝衰竭临床疗效。方法将2003年1月至2007年12月间住院的慢加急性(亚急性)肝衰竭患者随机分为治疗组及对照组,对照组仅给予内科综合治疗,治疗组在此基础上加丽珠肠乐及莫沙必利口服治疗,疗程1月。结果治疗组临床疗效优于对照组(P<0.01),治疗组治疗后出血、感染、肝性脑病、肝肾综合征、腹水并发症少于对照组。结论丽珠肠乐及莫沙必利治疗慢加急性(亚急性)肝衰竭临床疗效显著,预后明显改善。

Objective To observe clinic effect of Bifidobiogen - Livzon and Mosapride on patients with liver failure. Methods 42 cases with subacute liver failure, who were admitted to our hospital from January of 2003 to December of 2007, were randomly divided into two groups （treatment group and control group）. The control group was only treated with comprehensive treatment for one month. While for the treatment, besides the comprehensive treatment, Bifidobiogen - Livzon and Mosapride orally were added at the same time. Results The clinic effect of treatment group was significantly prior to control group （P 〈 0. 01 ）. The incidence of complication in treatment group, such as hemorrhage, infection, hepatic eneephalopathy, hepatorenal syndrome, was significantly lower than that in control group. Conclusion The curative effect with Bifidobiogen - Livzon and Mosapride on subacute liver failure is significant.